{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:28:02Z","timestamp":1790504882098,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.7759\/cureus.13047","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T09:25:50Z","timestamp":1612171550000},"source":"Crossref","is-referenced-by-count":28,"title":["Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial \u2013 Biochemical)"],"prefix":"10.7759","author":[{"given":"Flavio A","family":"Cadegiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gustavo Wambier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Goren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan WJ","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, et al.. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 382:1708-1720. 10.1056\/NEJMoa2002032","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00304-9","article-title":"Impact of sex and gender on COVID-19 outcomes in Europe","volume":"11","author":"Gebhard C","year":"2020","unstructured":"Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020, 11:29. 10.1186\/s13293-020-00304-9","journal-title":"Biol Sex Differ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.079","article-title":"Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the \"Gabrin sign\"","volume":"83","author":"Wambier CG","year":"2020","unstructured":"Wambier CG, Va\u00f1o-Galv\u00e1n S, McCoy J, et al.. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the \"Gabrin sign\". J Am Acad Dermatol. 2020, 83:680-682. 10.1016\/j.jaad.2020.05.079","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13443","article-title":"A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity","volume":"19","author":"Goren A","year":"2020","unstructured":"Goren A, Va\u00f1o-Galv\u00e1n S, Wambier CG, et al.. A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020, 19:1545-1547. 10.1111\/jocd.13443","journal-title":"J Cosmet Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.099","article-title":"Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign","volume":"83","author":"Wambier CG","year":"2020","unstructured":"Wambier CG, Va\u00f1o-Galv\u00e1n S, McCoy J, Pai S, Dhurat R, Goren A. Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. J Am Acad Dermatol. 2020, 83:e453-e454. 10.1016\/j.jaad.2020.07.099","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16953","article-title":"Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men (Epub ahead of print)","author":"Goren A","year":"2020","unstructured":"Goren A, Wambier CG, Herrera S, et al.. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men (Epub ahead of print). J Eur Acad Dermatol Venereol. 2020, 10.1111\/jdv.16953","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17021","article-title":"5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia (Epub ahead of print)","author":"McCoy J","year":"2020","unstructured":"McCoy J, Cadegiani FA, Wambier CG, et al.. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia (Epub ahead of print). J Eur Acad Dermatol Venereol. 2020, 10.1111\/jdv.17021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.479","article-title":"Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)","volume":"31","author":"Montopoli M","year":"2020","unstructured":"Montopoli M, Zumerle S, Vettor R, et al.. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020, 31:1040-1045. 10.1016\/j.annonc.2020.04.479","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020, 181:271-280. 10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-1010","article-title":"The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis","volume":"4","author":"Lucas JM","year":"2014","unstructured":"Lucas JM, Heinlein C, Kim T, et al.. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014, 4:1310-1325. 10.1158\/2159-8290.CD-13-1010","journal-title":"Cancer Discov"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01697-5","article-title":"Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic","volume":"18","author":"Kyrou I","year":"2020","unstructured":"Kyrou I, Karteris E, Robbins T, Chatha K, Drenos F, Randeva HS. Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic. BMC Med. 2020, 18:220. 10.1186\/s12916-020-01697-5","journal-title":"BMC Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17004","article-title":"Clinical symptoms of hyperandrogenic women diagnosed with COVID-19 (Epub ahead of print)","author":"Cadegiani FA","year":"2020","unstructured":"Cadegiani FA, Lim RK, Goren A, et al.. Clinical symptoms of hyperandrogenic women diagnosed with COVID-19 (Epub ahead of print). J Eur Acad Dermatol Venereol. 2020, 10.1111\/jdv.17004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13455","article-title":"Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19?","volume":"19","author":"McCoy J","year":"2020","unstructured":"McCoy J, Wambier CG, Vano-Galvan S, et al.. Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19?. J Cosmet Dermatol. 2020, 19:1542-1543. 10.1111\/jocd.13455","journal-title":"J Cosmet Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00626-0","article-title":"Repurposing existing drugs for COVID-19: an endocrinology perspective","volume":"20","author":"Cadegiani FA","year":"2020","unstructured":"Cadegiani FA. Repurposing existing drugs for COVID-19: an endocrinology perspective. BMC Endocr Disord. 2020, 20:149. 10.1186\/s12902-020-00626-0","journal-title":"BMC Endocr Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00453","article-title":"Spironolactone: an anti-androgenic and anti-hypertensive drug that may provide protection against the novel coronavirus (SARS-CoV-2) induced acute respiratory distress syndrome (ARDS) in COVID-19","volume":"7","author":"Cadegiani FA","year":"2020","unstructured":"Cadegiani FA, Wambier CG, Goren A. Spironolactone: an anti-androgenic and anti-hypertensive drug that may provide protection against the novel coronavirus (SARS-CoV-2) induced acute respiratory distress syndrome (ARDS) in COVID-19. Front Med (Lausanne). 2020, 7:453. 10.3389\/fmed.2020.00453","journal-title":"Front Med (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110112","article-title":"Spironolactone may provide protection from SARS-CoV-2: targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)","volume":"143","author":"Cadegiani FA","year":"2020","unstructured":"Cadegiani FA, Goren A, Wambier CG. Spironolactone may provide protection from SARS-CoV-2: targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Med Hypotheses. 2020, 143:110112. 10.1016\/j.mehy.2020.110112","journal-title":"Med Hypotheses"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00136.2020","article-title":"Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?","volume":"318","author":"Cadegiani FA","year":"2020","unstructured":"Cadegiani FA. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?. Am J Physiol Endocrinol Metab. 2020, 318:E587-E588. 10.1152\/ajpendo.00136.2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16956","article-title":"Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients (Epub ahead of print)","author":"McCoy J","year":"2020","unstructured":"McCoy J, Wambier CG, Herrera S, et al.. Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients (Epub ahead of print). J Eur Acad Dermatol Venereol. 2020, 10.1111\/jdv.16956","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000471752","article-title":"Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia","volume":"20","author":"Vermeulen A","year":"1991","unstructured":"Vermeulen A, Giagulli VA, De Schepper P, Buntinx A. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia. Eur Urol. 1991, 20:82-86. 10.1159\/000471752","journal-title":"Eur Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.74.3.1371291","article-title":"Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia","volume":"74","author":"McConnell JD","year":"1992","unstructured":"McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992, 74:505-508. 10.1210\/jcem.74.3.1371291","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-88952\/v1","article-title":"Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial) [PREPRINT]","author":"Cadegiani FA","year":"2020","unstructured":"Cadegiani FA, Goren A, Wambier CG, McCoy J. Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial) [PREPRINT]. Res Sq. 2020, 10.21203\/rs.3.rs-88952\/v1","journal-title":"Res Sq"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/50511-early-antiandrogen-therapy-with-dutasteride-reduces-viral-shedding-inflammatory-responses-and-time-to-remission-in-males-with-covid-19-a-randomized-double-blind-placebo-controlled-interventional-trial-eat-duta-androcov-trial---biochemical","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:14Z","timestamp":1707506954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/50511-early-antiandrogen-therapy-with-dutasteride-reduces-viral-shedding-inflammatory-responses-and-time-to-remission-in-males-with-covid-19-a-randomized-double-blind-placebo-controlled-interventional-trial-eat-duta-androcov-trial---biochemical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.13047","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}